- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Galapagos N.V.
Industry Sector: HealthTechnology
CEO: Paulus Stoffels, MD
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: 21.36
Exchange/Ticker 1: Euronext Amsterdam:GLPG
Exchange/Ticker 2: NASDAQ:GLPG
Latest Market Cap: $1,708,183,261
BioCentury | Jan 9, 2025
Deals
Makeover for Gilead-Galapagos deal to yield newco primed for BD
Latest strategic move under Stoffels to yield two public entities, layoffs at parent company
BioCentury | Oct 8, 2024
Management Tracks
Veteran investor Oleg Nodelman joins Galapagos board
Plus: New CEOs at QuantX, Oak Hill, and updates from Every Cure, Mosaic, Anixa and more
BioCentury | Oct 3, 2024
Management Tracks
New chairs for Progentos, Curve and Eligo
Plus: Nxera names BMS vet Sugita CMO, Japan president, and updates from Achieve, Every Cure and more
BioCentury | Jun 4, 2024
Deals
Deals Report: Two pharmas license neuro assets, and M&A momentum continues
Plus: Galapagos-Adaptimmune enter TCR T cell deal, and digital therapeutics pioneer Akili opts for merger
BioCentury | Feb 22, 2024
Finance
Venture report: Frontier enters clinic with $80M round; ORI’s new $260M fund
Plus: Launches for Sofinnova-backed AI company Bioptimus, peptide start-up Insamo
BioCentury | Feb 15, 2024
Emerging Company Profile
BridGene: a pairwise approach to chemoproteomics for hard targets
The California company’s IMTAC screening platform for hard-to-drug targets has found partners in Takeda and Galapagos
BioCentury | Oct 31, 2023
Deals
Oct. 31 Quick Takes: Lilly buying Beam’s opt-in rights for Verve base editing programs
Plus: GSK buys Janssen’s rights to Arrowhead HBV product and more from Galapagos, Sarepta, Amgen, LianBio and X4
BioCentury | Oct 25, 2023
Management Tracks
Korro promoting Chappell to COO, adding Pearson to board
Plus: 3T hires Irving and updates from Q32 Bio, Garuda and Fibrocor
BioCentury | Sep 1, 2023
Finance
The Cystic Fibrosis Powerhouse: Vertex
Back to School 2023 case study: How Vertex kept raising the bar to dominate a therapeutic space
BioCentury | Aug 5, 2023
Regulation
Aug. 4 Quick Takes: Sage-Biogen get FDA approval for one of two depression indications
Plus: Galapagos trims Jyseleca guidance, seeks options; and updates from Mesoblast, Lilly, Sino and more
Items per page:
1 - 10 of 572